Volition is a leading epigenetics biomarker company, renowned for its proprietary immunoassay approach to profiling cell-free circulating nucleosomes. Our fully quantitative assays have demonstrated significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases. Our fee-for-service portfolio, Nu.Q® Discover, encompasses a range of assays targeting biomarkers associated with epigenetic inhibitors (HDACi, LSDi, EZH2i, EEDi), as well as innate immune activation (NETosis). Nu.Q® assays effectively correlate with disease and tumour burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes assay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using Mass Spec, and Toxicity Monitoring assays.
Discover more at www.volition.com and join us at the Next Generation Immuno-Oncology Conference to explore how we can support your projects.
GemPharmatech is a global company providing high-quality products and model systems for discovery, testing, development and production of new drugs and therapeutic solutions. GemPharmatech is one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners across the world. With advance gene editing technology, GemPharmatech has created and produced a large collection of over 14,000 transgenic mouse models for therapeutic applications.
Veracyte is a pioneering, global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment. Veracyte offers customized multi-omics tools and expertise to our biopharmaceutical partners, helping them advance their therapeutic discovery, development and commercialization programs.
ANGLE has worked towards, and received in 2022, US Food and Drug Administration (FDA) clearance for their Parsortix ® PC1 System for use with metastatic breast cancer (MBC) patients. This marks a significant achievement as the first ever FDA cleared product for harvesting circulating tumour cells from MBC patient blood samples for user-validated subsequent analysis. Creating new possibilities in the era of personalised cancer medicine, with the ability to repeat a non-invasive liquid biopsy.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
Canopy Biosciences, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary technology ChipCytometry™ is a quantitative multiplex immunofluorescence imaging method for the spatial analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services™ with our CLIA-certified laboratory, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction.
-.png)
Ground Truth Labs (GTL) has developed AI-powered computer vision algorithms to quantify complex spatial biomarkers from digital images of standard histopathology slides. Analysis is non-tissue destructive and results can be provided in near real-time, powering patient stratification in clinical trials and effectively measuring response to intervention.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”) focused exclusively on the design and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors and aims to become the partner of choice for companies developing cell and gene therapies. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators in this field. Focused on vector design, and preclinical and GMP manufacturing of lentivirus and gamma-retrovirus vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk.
Novogene utilises scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realise their research goals in the rapidly evolving world of genomics. With over 2,000 employees, multiple locations around the world, 37 NGS related patents, and over 670 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. In this conference, we will exhibit the latest genome sequencing solutions.
Company Description: Sino Biological is a leading bio-reagents manufacturer, dedicated in providing the scientific community with high-quality recombinant protein and antibody reagents to promote life science research and drug discovery. The company has the biggest validated recombinant protein bank (6500+) in the world as well as elite antibodies (14,000+), covering existing drug targets, Immune checkpoints, biomarkers, cytokines, viral proteins, etc. Several robust recombinant expression platforms and antibody discovery methods have been established and are available for customized contracted research projects.
Sino Biological Europe GmbH is the Europe site of Sino Biological, who sits in Frankfurt, Germany, with a local sales and service team, as well as our protein inventory.
Antibody Analytics specialise in providing high-quality data and solutions for biopharmaceutical companies facing scientific challenges. Leveraging expertise in immuno-oncology, we offer in vitro assay systems that model immune cell interactions in the tumour microenvironment and beyond. Our focus extends to novel therapeutic modalities aimed at modulating these processes for oncology and other disease indications. Led by skilled scientists, we deliver tailored bioassays and patented platforms to support complex drug pipelines, including antibody-based therapeutics, small molecules, and advanced cell therapies
